Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...Just received my 3rd call from reps informing me about the details of the tender offer. I told this one that I felt the offer was grossly under valued and that my average cost was xyz which is much more than the offer. ...so, I was not going to tender my shares. The rep said she would put the note in her spreadsheet. For what it's worth.
Looks like we have an engineered sell off in the works. That aught to scare a few more shares out of the wood work. Hold on everyone
I believe they are calling names in alpha order. My family members have received calls and it was in alpha order. We told them we were holding because the price was inadequate.
To my knowledge, there have been NO trades close to the offer price since the announcement of the buyout.
I think there is merit to the trades happening at this point.
Interesting, some shares traded at $8.51, and $8.50..
Maybe some news coming?
The FINANCING acknowledgment is the important item, not the inclusions in the indexes...
It should mean that we FINALLY get the Phase II studies to begin!
From this mornings news , Paul Wotton confirming that the financing IS COMPLETED!
Now we just need the phase II program to be commenced!
Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices
Date : 06/30/2015 @ 8:00AM
Source : Business Wire
Stock : Ocata Therapeutics (MM) (OCAT)
Quote : 5.05 0.0 (0.00%) @ 8:03AM
Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices
"We are pleased to be added to these Russell indices, another important milestone in improving our visibility among the investment community," said Paul K. Wotton Ph.D., President and CEO of Ocata Therapeutics, who added “Following our recently completed institutional equity financing, we are well-positioned to initiate our phase 2 clinical trial for dry-AMD and our pivotal trial for SMD, both debilitating disease states with no effective therapeutic options and where we are dedicated to bringing these important therapies to patients in need.”
Uh oh; Mid day bear attack...
Must be some news coming soon.
Someone wants cheap shares.
New Press release link and copy
http://ir.ocata.com/press-releases/detail/2778
About Us Our Approach Research & Development Clinical Trials Investor & Media Contact
Ocata Therapeutics, Inc.
Investor & Media
Press Releases
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City.
Related Links
PDF
Release PDF
“Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough cell based therapies,” said Dr. Paul K. Wotton, president and chief executive officer of Ocata Therapeutics. “Bob’s hard work and dedication has been translated successfully into clinical programs with a potentially transformative treatment for macular degenerative diseases, such as Stargardt’s and dry Age-related Macular Degeneration, where patients eventually lose their vision and for which there are no cures available today.”
The Forum will provide a high resolution overview of today’s complex global economic, political, national security, and business landscape critical for investment and policy concerns. Dr. Lanza will speak in the morning session, which will cover the future of healthcare, energy, and other sectors. In addition to Dr. Lanza, the Forum will bring together a critical mix of thought leader’s and game-changers “who are redefining our world,” including Mort Zuckerman, publisher of U.S. News & World Report and Daily News, Chris Hughes, co-founder of Facebook and owner of the New Republic, Jack Bogle, founder of The Vanguard Group, Michael Chertoff, former Secretary of Homeland Security, and Peter Peterson, former Secretary of Commerce.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.
About Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of vision loss in people over the age of 50. Every year in the USA there are 1.8 million patients newly diagnosed with dry AMD which occurs when light-sensitive photoreceptor cells in the macula, located in the center of the retina, slowly break down, causing vision loss as a result. Photoreceptor breakdown is a consequence of loss or damage to the RPE layer. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD and the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people in the United States. It is an orphan disease and loss of vision is an inevitable aspect of SMD, with more than half of the patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, it occurs as a result of damage to the RPE layer and there are no treatments currently approved to prevent or slow the vision loss associated with SMD.
Ocata Therapeutics, Inc.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com
Source: Ocata Therapeutics, Inc.
Released May 11, 2015
Overview
Press Releases
Events & Presentations
Financials & Filings
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
NASDAQ: OCAT
Price:
6.28
Change:
Day High:
Day Low:
Volume:
0
05/08/2015 04:00 PM EDT
View Detailed Stock Data »
Investor Relations
Westwicke Partners
John Woolford
T: (443) 213-0506
john.woolford@westwicke.com
©2014 Ocata Therapeutics, Inc. All rights reserved.
Legal Disclaimer
About Us
Overview
Leadership
The Meaning of Ocata
Careers
Contact Us
Our Approach
A New Pillar of Medicine
Market Insights
Our Regenerative Approach
Enhancing Quality of Life
World-Class Scientists
Research & Development
Pipeline Overview
Regenerative Ophthalmology
Other Regenerative Medicine Programs
Scientific Papers
Clinical Trials
Ongoing Clinical Trials
Disease Information
Investor & Media
Overview
Press Releases
Events & Presentations
Financials & Filing
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
Contact
Site Design: Monderer Design
Thank you Aye. The last line is important, and I'm glad they reiterated same.
Any news from the conference call?
Unfortunately, I got tied up and couldn't dial in.
From the looks of the after hours bid /ask numbers, it was just same ol same ol...
Ocata Therapeutics, Inc.
Investor & Media
Press Releases
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the First Quarter of 2015
Call Scheduled for Thursday, May 7, 2015 at 4:30 P.M.
Related Links
PDF
Release PDF
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, May 7, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the first quarter of 2015.
Interested parties may access the call live by dialing (800) 753-0487 (US) or (913) 312-0713 (international) and using conference ID 3671771.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Ocata website, www.ocata.com. A replay of the webcast will be archived on Ocata’s website for 90 days.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.
About Age-related Macular Degeneration
Age-related macular degeneration is the leading cause of vision loss in people over the age of 50. Every year in the USA there are 1.8 million patients newly diagnosed with dry AMD which occurs when light-sensitive photoreceptor cells in the macula, located in the center of the retina, slowly break down, causing vision loss as a result. Photoreceptor breakdown is a consequence of loss or damage to the RPE layer. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD and the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people in the United States. It is an orphan disease and loss of vision is an inevitable aspect of SMD, with more than half of the patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, it occurs as a result of damage to the RPE layer and there are no treatments currently approved to prevent or slow the vision loss associated with SMD.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com
Source: Ocata Therapeutics, Inc.
Released May 4, 2015
Overview
Press Releases
Events & Presentations
Financials & Filings
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
NASDAQ: OCAT
Price:
7.25
Change:
-0.13
Day High:
7.48
Day Low:
7.18
Volume:
129,559
05/01/2015 03:59 PM EDT
View Detailed Stock Data »
Investor Relations
Westwicke Partners
John Woolford
T: (443) 213-0506
john.woolford@westwicke.com
©2014 Ocata Therapeutics, Inc. All rights reserved.
Legal Disclaimer
About Us
Overview
Leadership
The Meaning of Ocata
Careers
Contact Us
Our Approach
A New Pillar of Medicine
Market Insights
Our Regenerative Approach
Enhancing Quality of Life
World-Class Scientists
Research & Development
Pipeline Overview
Regenerative Ophthalmology
Other Regenerative Medicine Programs
Scientific Papers
Clinical Trials
Ongoing Clinical Trials
Disease Information
Investor & Media
Overview
Press Releases
Events & Presentations
Financials & Filing
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
Contact
Site Design: Monderer Design
Here's the link and article. Great to see!
http://au.ibtimes.com/eye-stem-cell-therapy-first-clinical-trial-successful-asia-1444933
Eye Stem Cell Therapy: First Clinical Trial Successful In Asia
By Ruchira Dhoke on May 01 2015 10:00 PM
Share on facebook
34
Share on twitter
12
Share on linkedin
5
Share on google_plusone_share
More Sharing Services
A human embryonic stem cell line
(IN PHOTO) DATE IMPORTED:March 09, 2009A human embryonic stem cell line derived at Stanford University is seen in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009. The line was derived under controlled conditions that could make the cells useful for transplantation. The nuclei in green are stained for a protein that is found only in embryonic stem cells while blue represents the DNA of the surrounding feeder cells. U.S. President Barack Obama lifted restrictions on federal funding of human embryonic stem cell research, angering abortion opponents but cheering those who believe the study could produce treatments for many diseases. REUTERS
In a recent development, a team of scientists in Korea has successfully injected human embryonic stem cell (hESC)-derived retinal support cells into the eyes of four men suffering from macular degeneration.
Macular degeneration is an age-related medical condition that usually affects older people ( over 50 years), resulting in loss of vision caused due to the damage to the visual field or the macula .It is one of the leading cause of blindness and visual impairment with about 30-50 million people suffering from it globally. The diseased are unable to read or recognise faces, however, they can carry on with their other activities of daily life since their peripheral vision remains intact.
The researchers for their study treated two men, aged 65 and 79, with dry age-related macular degeneration, while a 40-year-old man and a 45-year-old man were both treated for Stargardt macular dystrophy, an earlier-onset inherited disease. The results of the study, published in the journal Stem Cell Reports, showed that among the four, the three men experienced vision improvements in their treated eyes after a year of following the procedure, while the fourth man’s vision did not show much improvement.
The clinical trial was initiated by a Korean company CHA Biotech, whereas Ocata provided the hESCs and some methodological instruction. Robert Lanza, the study co-author and chief scientific officer at Ocata, says, “Together with the results here in the US, I think this bodes well for the future of stem cell therapies.”
The success of the clinical trial has raised hopes for the scientist working in the field of regenerative medicine by providing a strong evidence that injecting hESC-derived cells is feasible and might be of therapeutic use in the future.
Earlier in 2012 and 2014, there were similar studies published in The Lancet which demonstrated that hESC-derived cells could be injected into the space behind the retina safely in patients suffering with macular degeneration.
Since the size of the trial carried out was small, Lanza feels that it is too early to conclude whether the treatment systematically improves vision in patients. However, he went on the record and said that the patients did experience vision improvements because of the infusion of new retinal pigment epithelium, or RPE, cells which otherwise are destroyed by macular degeneration.
Another significant discovery made by the team was that the transplanted RPE cells did not form tumours or differentiate into other type of cells. To this, Lanza adds, “Regulators don’t really want to see a tooth in the eye or they don’t want to see beating heart cells in the wrong place.”
On careful screening, the researchers were successful in avoiding the transplant of the cells that were not fully differentiated and hence did not form any unwanted tissues. Also, the patients’ immune systems did not reject the transplanted cells.
To contact the writer, email:ruchira.dhoke@gmail.com
From OCAT website: More exposure to the outside world: It's a good thing!
Upcoming Events
Cowen and Company 35th Annual Health Care Conference
March 3, 2015 • 9:20 am ET
I have TDAmeritrade and my screen says NASDAQ
With this volume, it may suggest that there is some covering today.
I don't really care if they cover now. At some point there will be a squeeze that refreshes!
I believe the mgmt. knows what they are doing, and it seems that they want the shorts to suffer. IMO
Good luck to all
The up-listing has not happened yet; the target audience won't buy the stock on this current exchange. Give it 'til Thursday when it is actually listed on the NASDAQ.
Great volume today!
Here we go again ! TD Ameritrade: OCAT posted this morning as symbol not found.
What the heck!
TD Ameritrade now has OCAT listed last trade 6.64 - .26
Where the exchange is usually listed there is (-)
That's what comes up when you search ocat on TD Ameritrade...you are right, it's data seems off
TTHI | TRANSITION THERAPEUTICS INC COM NEW and it's on NASDAQ !
Something's up this morning. My TD Ameritrade acct shows symbol not found, where OCAT is listed.
AH just found new symbol
TTHI | TRANSITION THERAPEUTICS INC COM NEW
Something's up this morning. My TD Ameritrade acct shows symbol not found, where OCAT is listed.
link from OCAT website http://ir.stockpr.com/ocata/quote
Look at the closing price and there is an H after it...key at the bottom says it's halted. .Maybe old news or is it halted again?
It seems to be trading, it's just back on the OTC for some reason...
Well my TD Ameritrade account has clearly reverted to Pink Sheets from what was listed as Nasdaq on Friday.
Just tried to make an after hours trade on TD Ameritrade...says the security is not eligible for this market (After market).
That is my point; insiders buy when they see $$ in the future.
If they, (insiders) show no interest, outsiders follow the leader and leave the buying to the traders. A lose, lose situation for longs.
The conclusion can be made that the company is not worth what they
imply it to be worth. Since outsiders have no direct window to the inside, they must depend on "gestures" (like insider buying) to assure us that we are not just fools.
Long and waiting for assurances from the big guys.
Probably true; there were a fair amount of 1000 share+ trades today.
Gotta love it, we will be up-listing (hopefully) in about a month.
Few trust people who don't have any personal "skin" in the game.
Even just some level of buying would help.
At the very least, they should shun the constant selling of their
awarded shares. ...They make it look like they have no faith in their company.
What this stock needs is for the insiders to buy some stock.
Look at this headline from today.
"Seadrill (SDRL) Stock Surging Today After Chairman Fredriksen Increases Stake"
If the insiders won't buy it, why should anyone else feel it's a buy?
Show me the money!
Go OCATA
At even 15 million shares per day, that's a long period for them to unload everything. Volume has not been that great lately.
They will be depressing the pps for quite a while.
When do they get their new shares delivered?
Just remember, no matter what news comes out, there are now paid off litigants with hundreds of millions of shares that will likely add a significant down draft for the PPS.
...basically the same thing that happened when the last published article came out.
So, are we up or down on Tuesday?
Looks like Smooth Sailing this afternoon. We will likely move up through Wednesday afternoon. If The New England Journal has our data; who knows?
What does this mean?
Notice of Effectiveness (effect)
Date : 06/06/2013 @ 6:02AM
Source : Edgar (US Regulatory)
Stock : Advanced Cell Tech (ACTC)
Quote : 0.0781 -0.0017 (-2.13%) @ 9:58AM
Nice, starting today with some pre-market buys.
Up up and away!
Mark Zuckerberg's 2012 pay was $2 million ...this from Wall St. Jrnl's Market Watch.
How much does Rabin get paid? I mean this is not a profitable venture yet, like Face Book right?
Sure makes you wonder the motives.
Pardon my missing any info... but wasn't Gary supposed to present yesterday at 3:45?
What's the time for today?
Thanks.
Go ACTC
It could be that they are delaying the good news to help us all out. Remember when the Lancet news came out, and it was immediately followed by the lawsuit fiasco?
We need to put the final lawsuits to bed before the trial updates hopefully, good news is disclosed. Why waste the good news with the "jury still out" hanging over our heads. IMO
They should be publishing that data soon I believe.
Anyone have any idea when that will be available?